Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib versus dupilumab in children with moderate to severe atopic dermatitis
NL-OMON59318Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of upadacitinib and dupilumab in atopic dermatitis (AD) (4 arms), sponsored by AbbVie Inc. Primary endpoints: EASI 75 at Week 16 and vIGA-AD 0/1 with at least 2-point improvement at Week 16. Started Dec 2024; status: active, not recruiting.
02
Drugs
upadacitinibdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON59318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59318.